Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
posted on
Jan 26, 2023 01:08PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
From the article, this looks like it could be a concern......
....In addition to failing the primary endpoints, the Keytruda combo group experienced a greater amount of serious adverse events, according to the news release....